[Optimization of enuresis therapy in children using transcranial magnetotherapy].
A total of 58 children (age from 6 to 14 years) suffering from nocturnal enuresis (NE) were divided into two groups. The study group received basic therapy (driptan dose was reduced to 2.5 mg twice a day) in combination with transcranial bitemporal magnetotherapy (TcMT). The control group received placebo TcMT and basic therapy. It is shown that addition of TcMT to reduced basic therapy lowered the score of imperative voiding symptoms 1.3-fold, number of enuresis patients 1.7-fold, volume of the bladder 6.8 months after the treatment 1.9-fold, corrected vegetative status and activity of the subcortical nervous center in 24% children according to cardiointervalography versus the controls. Thus, TcMT improves clinical effect in NE patients in 2-fold reduction of pharmacological burden.
Otpushchennikova
T V
TV
Kazanskaia
I V
IV
Volkov
S V
SV
Raĭgorodskaia
Iu M
IuM
D000293:Adolescent; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000187:drug effects / Q000502:physiology; D002648:Child; D003131:Combined Modality Therapy; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D053206:Nocturnal Enuresis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D018697:Nootropic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D012720:Severity of Illness Index; D050781:Transcranial Magnetic Stimulation / Q000379:methods*; D016896:Treatment Outcome; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use
D000892:Anti-Infective Agents, Urinary; D008333:Mandelic Acids; D018697:Nootropic Agents; D014803:Vitamin B Complex; C005419:oxybutynin